Search company, investor...

Predict your next investment

GT Capital company logo
Corporate Venture
gtcap.cn

Investments

15

Portfolio Exits

3

About GT Capital

GT Capital is the investment arm of Juneyao and AJ Group.

Headquarters Location

Room 302, 3/F, Jinwaitan International Plaza 100 Zhongshan South Rd., Huangpu District

Shanghai, Shanghai,

China

+86

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest GT Capital News

Metrobank and GT Capital Holdings Group pledge over P200M for COVID-19 crisis response

Mar 18, 2020

Inquirer Business / 04:44 PM March 18, 2020 The Metrobank and GT Capital Holdings group on Wednesday said they stand with all Filipinos in facing the challenges brought on by COVID-19 pandemic that has sickened over 200 people in the country. “The Ty family-led companies are pledging support to manage the disruption and provide meaningful assistance to customers, employees, and partners who most need help in these difficult times,” Metrobank said in a statement. ADVERTISEMENT The banking firm said aside from the assistance already being extended to impacted customers and displaced employees, a pledge of a P200 million fund would go to initiatives directly supporting the fight against the virus. “These initiatives will be managed by the respective Foundatiowards ns of the Group and will start with efforts to produce the test kits developed by the University of the Philippines-National Institutes of Health (UP-NIH) and the purchase of Personal Protective Equipment (PPE) for frontline health workers,” Metrobank said. FEATURED STORIES

GT Capital Investments

15 Investments

GT Capital has made 15 investments. Their latest investment was in TwinSolution as part of their Series B on May 5, 2023.

CBI Logo

GT Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

5/6/2023

Series B

TwinSolution

$23.15M

Yes

1

1/29/2022

Series B

Accurant BioTech

$20.44M

No

1

1/11/2022

Series C

Zencore Biologics

$100M

No

16

10/22/2021

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

8/26/2021

Seed VC - II

Subscribe to see more

Subscribe to see more

0

Date

5/6/2023

1/29/2022

1/11/2022

10/22/2021

8/26/2021

Round

Series B

Series B

Series C

Private Equity

Seed VC - II

Company

TwinSolution

Accurant BioTech

Zencore Biologics

Subscribe to see more

Subscribe to see more

Amount

$23.15M

$20.44M

$100M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

16

10

0

GT Capital Portfolio Exits

3 Portfolio Exits

GT Capital has 3 portfolio exits. Their latest portfolio exit was V-Test Semiconductor on October 26, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/26/2022

IPO

$99M

Public

1

4/22/2022

IPO

Subscribe to see more

$99M

Subscribe to see more

10

1/7/2022

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/26/2022

4/22/2022

1/7/2022

Exit

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

1

10

10

GT Capital Team

2 Team Members

GT Capital has 2 team members, including current Chief Financial Officer, Wang Bin.

Name

Work History

Title

Status

Wang Bin

Chief Financial Officer

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Wang Bin

Subscribe to see more

Work History

Title

Chief Financial Officer

Subscribe to see more

Status

Current

Subscribe to see more

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.